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Abstract 34 
Alzheimer’s disease (AD) is a progressive degenerative disorder of the brain and is the most 35 
common form of dementia. To-date no simple, inexpensive and minimally invasive 36 
procedure is available to confirm with certainty the early diagnosis of AD prior to the 37 
manifestations of symptoms characteristic of the disease. Therefore, if population screening 38 
of individuals is to be performed, more suitable, easily accessible tissues would need to be 39 
used for a diagnostic test that would identify those who exhibit cellular pathology indicative 40 
of mild cognitive impairment (MCI) and AD risk so that they can be prioritized for primary 41 
prevention. This need for minimally invasive tests could be achieved by targeting surrogate 42 
tissues, since it is now well recognized that AD is not only a disorder restricted to pathology 43 
and biomarkers within the brain. Human buccal cells for instance are accessible in a 44 
minimally invasive manner, and exhibit cytological and nuclear morphologies that may be 45 
indicative of accelerated ageing or neurodegenerative disorders such as AD. However, to our 46 
knowledge there is no review available in the literature covering the biology of buccal cells 47 
and their applications in AD biomarker research. Therefore, the aim of this review is to 48 
summarize some of the main findings of biomarkers reported for AD in peripheral tissues, 49 
with a further focus on the rationale for the use of the buccal mucosa (BM) for biomarkers 50 
of AD and the evidence to date of changes exhibited in buccal cells with AD. 51 
 52 
Keywords 53 
Alzheimer’s disease, peripheral biomarkers, buccal mucosa, mild cognitive impairment, 54 
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1. Need for predictive biomarkers of AD 60 
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States [1] and the 61 
most common form of dementia. AD patients have been reported with cognitive impairment 62 
characterized by impaired ability to register new information, reasoning, visuospatial 63 
abilities and language functions. AD patients also exhibit behavioural symptoms such as for 64 
instance, mood fluctuations, apathy, compulsive or obsessive behaviours and loss of 65 
interest, often correlated with loss of cognitive functions [2-5]. Previously, clinical diagnosis 66 
of AD were based upon criteria outlined by the National Institute of Neurological and 67 
Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related 68 
Disorders Association (ADRDA), published in 1984 including memory impairments, 69 
visuospatial and language impairment (aphasia) as measured by the Mini-Mental State 70 
Examination (MMSE) [6]. These criteria were recently revised by the NINCDS-ADRDA to 71 
incorporate biomarkers of brain amyloid-beta (cerebrospinal fluid (CSF) Amyloid-β 1-42, 72 
positive positron emission tomography (PET) amyloid imaging) and downstream neuronal 73 
degeneration (CSF Tau, magnetic resonance imaging of brain atrophy, PET imaging of 74 
fluorodeoxyglucose uptake) in the diagnosis of AD [5]. Although NINCDS-ADRDA does not 75 
encourage the use of such biomarkers within tests for routine diagnostic purposes, they can 76 
and should be used to increase certainty of diagnostic in research and clinical trials. 77 
However, the current suite of tests used in clinical diagnosis can only provide a possible or 78 
probable diagnostic of AD in living subjects and the definitive diagnostic can only be made 79 
during post-mortem. This is achieved by the observation of the extracellular senile plaques 80 
and intracellular neurofibrillary tangles in the specific areas of the brain such as the 81 
entorhinal cortex and hippocampus [7,8]. The number of new AD cases is dramatically 82 
increasing with an estimated 81.1 million people worldwide being affected by dementia by 83 
2040 [9] and since the pathogenic processes of AD are likely to begin years before clinical 84 
symptoms are observed, the need of predictive biomarkers has become urgent. Moreover 85 
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AD does not only alter the quality of life, health and wellbeing of those affected but also 86 
leads to a significant social financial burden [10,11]. 87 
 88 
2. Peripheral tissue as source for AD biomarkers 89 
A biomarker, as defined by the National Institutes of Health Biomarkers Definitions Working 90 
Group, is “a characteristic that is objectively measured and evaluated as an indicator of 91 
normal biological processes, pathogenic processes, or pharmacologic responses to a 92 
therapeutic intervention” [12]. A potential biomarker should be useful for detecting early 93 
stages of a disease and exhibit high levels of sensitivity and specificity.  The scientific 94 
community has been actively investigating potential early biomarkers of AD. Currently, the 95 
majority of investigators have used blood, CSF or brain imaging. In terms of direct brain 96 
imaging, Pittsburgh B (PiB) compound was used and shown to be able to readily detect 97 
amyloid-β (Aβ) protein aggregation forming senile plaques in specific regions of the brain, 98 
however it has been shown in some case reports that the accumulation of large plaques are 99 
necessary for PiB imaging to be useful [13,14]. Additionally, CSF has been used to identify 100 
changes in Aβ42 and Tau protein levels [15,16]. However, these methods of investigations are 101 
not ideal for screening populations since they are either too invasive and/or expensive 102 
[15,17,18]. Therefore, if screening of populations of individuals for the early detection of AD 103 
is to be performed, more suitable, easily accessible tissues need to be utilized introducing 104 
diagnostic tests at much lower costs together with high specificity and sensitivity. This need 105 
for minimally invasive tests could be achieved by targeting surrogate tissues reflecting 106 
systemic susceptibility as recent evidence indicates that AD is a disorder that is not 107 
completely restricted to pathology and biomarkers within the brain, but significant biological 108 
changes also appear in non-neural tissues such as fibroblasts, blood and buccal cells [19-23] 109 
and is summarized in Table 1.  110 
 111 
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2.1. Fibroblasts  112 
The plausibility that AD risk is reflected in cellular biomarkers in peripheral tissue has been 113 
investigated by studying well-known markers of genomic instability that have been reported 114 
to increase with age, and therefore suggest that the capacity for repair of DNA damage may 115 
also be altered in AD [24-26]. Micronuclei (MN) are a well validated and robust biomarker of 116 
whole chromosome loss and/or breakage that originate from chromosome fragments or 117 
whole chromosomes that lag behind at anaphase during nuclear division and have been 118 
shown to be predictive of increased cancer risk, cardiovascular mortality and have been 119 
found to be elevated in neurodegenerative disorders [27-30]. In fibroblasts for example, MN 120 
frequency has been shown to be increased with advancing age [31] as well as in AD [32]. 121 
Down’s syndrome is also considered a premature ageing syndrome with a high rate of 122 
conversion to dementia and is associated with abnormally high levels of DNA damage 123 
[33,34]. Furthermore, Down’s syndrome (trisomy 21) patients express brain changes by their 124 
4
th
 decade of life that are histopathologically indistinguishable from AD [35]. As the amyloid-125 
β protein precursor (AβPP) gene is encoded on chromosome 21 [36], it has been suggested 126 
that one of the underlying mechanisms of AD could be the altered gene dosage and 127 
subsequent expression of AβPP, leading to accumulation of the aggregating form of Aβ 128 
peptide following proteolysis. Peripheral tissue such as skin fibroblasts from familial and 129 
sporadic AD has been shown to exhibit a 2-fold increase in the number of trisomy 21 cells 130 
when compared to controls [35]. Moreover, an increase in immunostaining of amyloid 131 
peptides (Aβ40, Aβ42) as well as an imbalance between free cholesterol and cholesterol ester 132 
pools has been observed in fibroblasts of AD [37]. The capacity of fibroblasts to spread in 133 
culture was also observed to be altered in AD with a decrease of cytosolic free calcium 134 
(p<0.001) [38]. Furthermore an increase of total bound calcium in fibroblasts was observed 135 
when compared to age-matched controls [39]. 136 
 137 
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2.2. Olfactory epithelium  138 
Anosmia or olfactory dysfunction resulting in loss of smell is common in neurodegenerative 139 
diseases such as Parkinson’s or AD and may appear as one of the early symptoms. 140 
Furthermore, olfactory dysfunction has been found to be commonly associated with 141 
memory deficiency in transgenic mouse models of AD [40,41]. In humans, the olfactory 142 
epithelium was shown to be a peripheral tissue that exhibited increased oxidative damage in 143 
AD. HNE-pyrrole (a product of lipid oxidation) and heme oxygenase-1 (a catalytic enzyme 144 
involved in degradation of heme) levels were found to be increased in neurons and epithelial 145 
cells from olfactory biopsy sections in AD compared to healthy controls (p<0.002 and 146 
p<0.0001, respectively), thus confirming the presence of oxidative damage at a peripheral 147 
level in AD [42]. Increased levels of Aβ and hyperphosphorylated Tau were also observed in 148 
the olfactory epithelium in AD [21]. Detection was performed by immunohistochemistry and 149 
a significant increase in frequency of both Aβ (p<0.001) and hyperphosphorylated Tau 150 
(p<0.05) was observed when compared to controls [21]. Post-mortem neuropathological 151 
examination of participants’ brains were also undertaken and a significant correlation (r = 152 
0.37, p<0.001) was found between Aβ plaque frequency in olfactory epithelium and 153 
averaged Aβ frequency in multiple cortical regions (i.e. hippocampus, entorhinal cortex, 154 
amygdala, superior/middle temporal gyri, angular gyrus, mid-frontal gyrus, and anterior 155 
cingulate cortex) [21]. Additionally, there was a significant correlation found between 156 
hyperphosphorylated Tau in olfactory epithelium and hyperphosphorylated Tau in brains 157 
(p<0.05) [21]. Therefore, the presence of Aβ and Tau immunostaining could also be 158 
investigated in peripheral tissue such as olfactory epithelium for potential early AD 159 
biomarkers. 160 
 161 
2.3. Whole blood 162 
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Since blood can be sampled easily and may reflect pathological changes in AD, it is not 163 
surprising that this tissue has been commonly investigated as a source for AD biomarkers 164 
[43-45]. For instance, following completion of a genome-wide association study (Alzheimer’s 165 
Disease Neuroimaging Initiative) [46], TOMM40 (translocase of outer mitochondrial 166 
membrane 40) was found to be a potential gene associated with AD (TOMM40 risk alleles 167 
were two times more frequent than in controls) and therefore an additional risk for 168 
developing AD [46]. The expression of this gene has been found to be significantly down-169 
regulated in blood from AD compared to controls [44]. Another study, the Australian, 170 
Imaging, Biomarkers and Lifestyle study (AIBL) observed lower levels of red blood cell folate 171 
in AD patients compared to healthy controls (p=0.004), albeit serum folate did not show 172 
significant differences [47]. A recent study conducted by Leidinger et al. identified 140 173 
differentially expressed microRNAs (mi-RNAs), non coding RNAs that play key roles in the 174 
regulation of gene expression, in blood of Alzheimer’s patients when compared to controls 175 
and further validated a 12-miRNAs signature of AD [48]. Using this newly developed 176 
signature, AD patients were separated from the control group with 95.1% specificity and 177 
91.5% sensitivity. Additionally, this signature presented a separation of MCI versus control 178 
with 81.1% specificity and 87.7% sensitivity [48]. Although these studies on whole blood 179 
samples have shown interesting results, studies on blood components (i.e. white blood cells, 180 
platelets and plasma) have also brought to light several promising findings as discussed 181 
below. 182 
 183 
2.4. White blood cells  184 
Tau protein, one of the main proteins known to be associated with AD interacts with 185 
microtubules, actin filaments and intermediate filaments to play a key role in regulating the 186 
organisation and integrity of the cytoskeleton [49]. An increase in the phosphorylation levels 187 
of Tau was reported to occur due to the compromised function of protein phosphatase 2A in 188 
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AD brains [50,51]. Tau protein was shown to be elevated in CSF of AD patients and is an 189 
accepted biological marker of AD [15,16]. In lymphocytes, both phosphorylated and non 190 
phosphorylated forms of Tau were detected by Western blot and shown to be significantly 191 
increased in AD compared to controls (approximately 2-fold increase), with a direct 192 
correlation between phosphorylated Tau and disease duration [52]. Another protein, 193 
chitotriosidase (chitinase) a chitinolytic enzyme secreted by activated mononucleated cells 194 
that has previously been shown to exhibit a higher activity in CSF in AD [53,54], also showed 195 
a significantly increased level of expression (19-fold) in macrophages [55]. Evidence of the 196 
nuclear accumulation of γH2AX, a protein that becomes phosphorylated following induction 197 
of DNA double strand breaks, has been observed in astrocytes of AD brains [56]. Peripheral 198 
DNA damage, including single and double strand breaks, has been shown to increase in 199 
leukocytes of MCI and AD when compared to controls (p<0.001) [57]. Individuals with MCI 200 
have also been used to study biomarkers of AD since this group shows an approximate 50% 201 
of conversion into AD over 4 years [58] and it is interesting to note that the level of primary 202 
DNA damage is lower, although not significant, in AD compared with MCI [57]. This is 203 
suggestive that this type of DNA damage decreases as the disease progresses further. 204 
Oxidative stress which results in the accumulation of oxidized DNA base adduct 8-hydroxy-205 
2deoxyguanosine (8-OHdG) is also believed to be involved in a number of 206 
neurodegenerative diseases [59-61] and has been shown to occur prior to the pathology 207 
hallmarks of AD [62]. An approximate 5-fold increase in 8-OHdG was observed in CSF of AD 208 
compared with controls (p<0.001) and may partly explain the DNA damage that has been 209 
observed in AD cases [63]. The comet assay, which can be used to assess both single and 210 
double strand breaks in DNA, has also been utilized after enzyme treatment to demonstrate 211 
that peripheral leukocytes exhibit a significant increase in oxidative DNA damage markers 212 
i.e. oxidized DNA pyrimidines and purines in MCI and AD with respect to controls (p<0.002 213 
and p<0.001, respectively) [57]. More evidence has come from genomic instability markers 214 
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such as MN which were shown to increase in frequency in lymphocytes with age [64] and AD 215 
when compared to healthy controls [22,65,66].   216 
 217 
Another marker of genetic instability, telomere length, is known to change with ageing and 218 
in some cell types involves progressive telomere shortening. Telomeres are highly conserved 219 
DNA sequence repeats (of TTAGGG) involved in the maintenance of genome stability. 220 
Telomere length can be assessed by a variety of methods including southern blot, flow 221 
cytometry, quantitative fluorescence in situ hybridisation (FISH) or by quantitative reverse 222 
transcription-polymerase chain reaction (qRT-PCR) [67-70]. Shortened telomeres in blood 223 
have been shown to be associated with an increased risk of cardiovascular disease and 224 
degenerative disease such as cancers [71-73]. Telomere length has also been investigated in 225 
white blood cells of confirmed AD cases and found to be significantly shorter in those of AD 226 
patients compared with young and old controls (p<0.0001) [19]. Studies have shown a 227 
decrease in telomere length in lymphocytes isolated from AD that was correlated (r = -0.77) 228 
with a decrease in the MMSE scores indicating a possible link between telomere length and 229 
cognitive decline in AD [74].  230 
 231 
Lymphocytes from AD cases or first degree relatives also show substantial differences 232 
relative to controls with respect to intracellular lipid pods [75]. Oil Red O (ORO) staining 233 
(indicative of accumulation of neutral lipids) has been used to demonstrate higher levels of 234 
neutral lipids in peripheral blood mononuclear cells of probable AD patients [75]. The study 235 
by Pani et al. 2009 demonstrated that approximately 85% of isolated lymphocytes from AD 236 
had high neutral lipids levels (mainly cholesterol ester) as well as an increased content of the 237 
Acetyl-Coenzyme A acetyltransferase-1 protein (the enzyme that catalyses the formation of 238 
cholesterol esters in cells) compared with cognitively normal age-matched controls. These 239 
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data suggest that intracellular cholesterol ester levels are systemically increased in AD 240 
patients and support the hypothesis of altered lipid metabolism in AD.  241 
 242 
AD pathology has also been linked to proteins that are involved in maintaining the cell-cycle. 243 
For example hyperphosphorylated Tau is linked to the activity of cyclin-dependent protein 244 
kinases [76,77]; AβPP metabolism is monitored by cell-cycle dependent changes and is also 245 
up-regulated by mitogenic stimulation [78-80]; and finally Aβ (a product of AβPP processing) 246 
has been identified as mitogenic in in vitro studies [81,82]. A recent study using lymphocytes 247 
from AD patients demonstrated the potential of G1/S checkpoint proteins as biomarkers of 248 
AD. In that study, increased expression of Cyclin E, Rb, CDK2 and E2F-1 was observed and 249 
gave specificity/sensitivity scores of 84/81%, 74/89%, 80/78% and 85/85%, respectively [83]. 250 
These studies suggest that altered cell-cycle mechanisms may be indirectly involved in the 251 
process of AD onset and development.  252 
 253 
2.5. Platelets 254 
Platelets have also been investigated in AD and found to express changes with the disease 255 
state. For instance the ratio of two isoform products of AβPP processing (130kDa/110kDa) 256 
that occurs in platelets was studied as a potential biomarker and found to be decreased in 257 
platelet membranes in AD and MCI compared with their respective controls [84,85]. The 258 
presence of phosphorylated and non phosphorylated Tau protein was detected by 259 
immunofluorescence as well as different variant forms of Tau using Western blot 260 
techniques. The different immunoreactive fractions of Tau separated by Western were 261 
combined to obtain a ratio of high (>80 kDa) and low (<80 kDa) molecular weight bands and 262 
when quantified by imaging was found to be significantly increased in AD compared to 263 
healthy controls (p=0.0001) [23].  The results from this study confirmed that peripheral 264 
markers such as platelet Tau isoforms could serve as potential biological markers of AD. 265 
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 266 
2.6. Plasma 267 
Plasma is obtained with relative ease and has been used widely to identify potential 268 
biomarkers of AD. Plasma sampled from AD individuals has previously shown an 269 
approximate 4.8-fold increase in chitotriosidase levels when compared to healthy controls 270 
(p<0.001) [86]. YKL-40, a homolog to chitotriosidase was recently described in early stages of 271 
AD with significantly higher protein levels found in CSF (p<0.0001) as well as in plasma 272 
(p=0.014) compared to controls [87,88], and more importantly, presented a strong ability to 273 
predict onset and progression of dementia [87]. For instance, it was found that a high YKL-274 
40/Aβ42 ratio in CSF demonstrated strong predictive values of a faster cognitive decline, and 275 
that levels of YKL-40 significantly correlated (r = 0.5948, p<0.0001) with levels of 276 
phosphorylated Tau in CSF [87]. Analysis of plasma has some advantages as an approach to 277 
population-based screening of AD as it is well accepted and less invasive than CSF sampling, 278 
for example. A review of longitudinal studies that examined plasma levels of Aβ indicates 279 
that higher baseline levels of Aβ40 might predict higher risk of conversion towards AD [89] 280 
and that higher levels of Aβ42 were also associated with a 3-fold increase of AD risk [20]. 281 
Importantly, higher level of baseline plasma amyloid in people free of dementia appears to 282 
be a predictive marker of a faster cognitive decline in those individuals who converts to AD 283 
[90]. An intensive study investigating biomarkers for diagnosis of AD in the Australian 284 
Imaging, Biomarkers and Lifestyle study of ageing (AIBL) cohort identified a list of 21 plasma-285 
based biomarkers that showed a significant fold change between AD and healthy controls. 286 
The top 10 biomarkers with the most differences (p<0.0001) were as follows; insulin like 287 
growth factor binding protein 2, pancreatic polypeptide, cortisol, vascular cell adhesion 288 
molecule 1, superoxide dismutase, interleukins 10 and 17, albumin, calcium and Zinc 289 
(isotope 66) [43]. More recently a study from Mapstone et al. [91] discovered and validated 290 
a list of 10 phospholipid fatty acids that were depleted in healthy controls who would 291 
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convert to MCI or AD within a 2-3 year timeframe This panel of metabolites was still 292 
depleted after conversion and allowed separation of converters from controls that remained 293 
cognitively normal with more than 90% accuracy. Importantly, the ROC curve generated in 294 
their study showed an area under the curve (AUC) of 0.96 and a specificity and sensitivity of 295 
both 90% [91]. The evidence discussed above suggests that AD is a systemic disorder 296 
involving a change in a myriad of biological parameters that can be reflected in peripheral 297 
tissues.  298 
 299 
3. Focus on buccal cells as a peripheral tissue 300 
Buccal mucosa (BM), like the brain and skin epithelium cells, are derived from differentiated 301 
ectodermal tissue during embryogenesis and therefore would be a potential surrogate non-302 
neural tissue that may have the potential to reflect the underlying pathological changes 303 
observed in AD. Buccal cells have been used as a source of tissue in a variety of biochemical 304 
and molecular biology studies using an assortment of different techniques to collect the cells 305 
including; cotton swabs [92], cytobrushes [92-94], a “swish and spit” method [95-97], a 306 
modified Guthrie card [98] and a method of rubbing cheeks against teeth to exfoliate cells 307 
[94]. The results from those studies demonstrated that high quantities of buccal cells (more 308 
than a million per sampling) could be obtained and then subsequently used in a variety of 309 
assays; such as DNA analysis using PCR or other genotype tests [95,96,99-102], for isolation 310 
of mRNA for gene expression profiling, Western blots for detection of proteins and 311 
immunocytochemistry [103-105], high-performance liquid chromatography (HPLC) [106] and 312 
ion transporter assays [107]. Ideally invasive procedures should be avoided in AD patients 313 
due to age and presenting medical issues, therefore buccal cells could offer an appropriate 314 
alternative as a relatively non-invasive and easily accessible source of tissue for analysis. 315 
Furthermore, buccal cells have been shown to be osmotically stable in hypotonic solutions 316 
including water [108] making them more easily processed with less risk of losing intracellular 317 
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contents during investigation procedures. Additionally, it has been found that buccal cells 318 
can be readily preserved during transportation for cytology and immunocytochemistry 319 
studies by isolation directly into buccal cell buffer [109]. Therefore it would be possible to 320 
isolate buccal cells from patients in remote regions and facilitate storage of samples in 321 
laboratories. 322 
 323 
3.1. Morphological changes in buccal cells 324 
For the BM to be a valuable tissue to study for biomarkers of AD, the BM would need to 325 
exhibit changes within the cells that correlate well with the disease state. Structurally, the 326 
BM is a stratified squamous epithelium consisting of four distinct layers [110-112] as shown 327 
in Figure 1. First the stratum corneum lines the oral cavity. Below this layer, is located the 328 
stratum granulosum, and the stratum spinosum containing populations of differentiated, 329 
apoptotic and necrotic cells. The next layer contains the rete pegs or stratum germinativum 330 
composed of basal cells, which, by cell division and DNA replication regenerate and maintain 331 
the profile, structure and integrity of the BM [113]. The basal cells are believed to 332 
differentiate and migrate to the keratinized surface layer in 7 to 21 days. With normal ageing 333 
the efficiency of cell regeneration decreases [112,114] resulting in a thinner epidermis and 334 
underlying cell layers [115]. The protective function of the stratum corneum is not altered 335 
[116] but the rete pegs adopts a more flattened appearance [117,118].  336 
 337 
Since buccal cells and the nervous system are derived from the same germ cell layer, the 338 
ectoderm, the regenerative potential of BM might be affected in parallel with the 339 
regenerative potential of the brain, which is found to be altered in AD [119]. One study 340 
investigated the BM’s different cell types and its composition in AD compared with age-341 
matched controls by the use of the buccal cytome assay [120]. Frequencies of the various 342 
cell types were scored and an alteration of the BM composition was shown to occur in AD. A 343 
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significant decrease in the frequency of basal cells, karyorrhectic and condensed chromatin 344 
cells (p<0.0001) were found in the AD cohort [120] as shown in Figure 2. The odds ratio of 345 
being diagnosed with AD for a combined karyorrhectic and basal cell frequency of <41 per 346 
1000 cells was shown to be 140 with a specificity of 96.8% and a sensitivity of 82.4% [120]. 347 
This segregation of cell types has also been shown in an automated manner using imaging 348 
analysis by laser scanning cytometry (LSC) [121], making this cytome assay more feasible for 349 
scoring on a larger study scale. Another study [122], aimed at assessing morphologic and 350 
cytometric aspects of cells of the oral mucosa of AD patients using the Papanicolaou staining 351 
method [123]. A visual assessment of cell types was made by microscopy and cytological 352 
parameters were measured using the Image J analysis software. The results of that study 353 
demonstrated a significant reduction in the number of intermediate cells (p<0.05) as well as 354 
in the nuclear:cytoplasmic area ratio (p<0.0001) in the AD group compared to the controls 355 
[122]. Both studies suggest that changes occur in the BM of those diagnosed with AD in 356 
terms of cytological features and cell type composition which may indicate a decrease in the 357 
regenerative capacity of the BM in AD.  358 
 359 
3.2. Cytokeratins – Biochemical cell type segregation 360 
The frequency of basal buccal cells as discussed in the previous section was found to be 361 
lower in AD, using the buccal cytome assay, which scores cells on morphological features. 362 
Therefore, an epithelial cell differentiation marker may allow a more definite and precise 363 
identification of basal cells, as compared with visual assessment by the buccal cytome assay. 364 
Indeed, buccal cells contain groups of structural proteins called cytokeratins (CK) [124], that 365 
are found to be expressed in a tissue specific manner [125,126]. Buccal cells normally 366 
express CK 4, 5, 13, 14 and possibly 19 depending on their cell types [125,127]; CK5 and 367 
CK14 are predominantly expressed in the basal layer but after a period of differentiation and 368 
migration, buccal cells begin expressing CK4 and CK13 accompanied with a progressively 369 
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reduced expression of CK5 and CK14 [128]. Furthermore, in other epithelial tissues such as 370 
the olfactory epithelium, basal cells were shown to express keratin 8 [129]. An example of 371 
the differences in cytokeratin immunostaining of buccal cells observed by our group is 372 
shown in Figure 3, where some cells were found to be positive for CK5 or CK13, others were 373 
both CK5 and CK13 positive, whilst yet another population of buccal cells were negative for 374 
CK5 and CK13 (Figure 3). Another study also showed that CK10 and CK8 were detected in 375 
low amounts in buccal cells using immunocytochemistry techniques [128]. Interestingly, 376 
differential expression of CK proteins, such as CK5, has been observed in carcinomas of the 377 
BM [127,130]. For instance, in mucoepidermoid carcinoma there was a strong correlation of 378 
high levels of CK5 expression (in oral mucosa) with poorer survival times (p<0.001). 379 
Specifically, at the completion of that study, 12 (of 13) patients with high levels of CK5 380 
expression were deceased, compared with 6 patients out of the 18 patients with the lowest 381 
values of CK5 expression [130]. In another study investigating dementia, levels of keratin 382 
autoantibodies when quantified by enzyme-linked immunosorbent assay (ELISA) in serum 383 
from patients with dementia, including 68% of patients diagnosed with AD, were found to be 384 
significantly increased compared to healthy controls (p<0.05) [131]. It was speculated that 385 
the increase in presentation of the keratin antigen to the immune-competent cells may 386 
result from the degenerative process of the brain. Since CK expression has been widely 387 
shown to differ in the BM with cell types [125,127], developmental stage [132,133], tissue 388 
differentiation [126,134-138] and pathological conditions [139-145], CK proteins could 389 
provide information on the proliferation and differentiation status which may be dependent 390 
on the disease state. Furthermore CK staining of BM may offer a convenient 391 
immunocytochemical manner of identifying cell types which could be scored in a 392 
quantitative and automated manner in AD patients using cellular imaging techniques such as 393 
laser scanning cytometry. 394 
 395 
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3.3. Buccal cells and Tau 396 
Accumulation of Tau forming neurofibrillary tangles (NFTs) in the brain is one of the main 397 
hallmarks of AD and has a major role in neuronal death. Hattori et al. [103] demonstrated 398 
the presence of putative multiple isoforms of Tau on Western blots that were the non-399 
phosphorylated form of Tau protein in buccal cells with the prominent appearance of two 400 
bands at approximately 65 kDa and 110 kDa, using the monoclonal BT-2 antibody. Using 401 
ELISA techniques, total Tau protein was shown to be significantly elevated within buccal cells 402 
of AD compared with age-matched controls (p<0.01). Furthermore, the increase in Tau of 403 
oral epithelium was shown to be significantly correlated with the Tau level in CSF (r = 0.43, 404 
p=0.011) and was also higher in AD subjects when diagnosed at a younger age of onset than 405 
with patients at later age of onset [103]. Therefore it is feasible that oral epithelium Tau may 406 
be a measurable and useful predictive biomarker of AD in buccal cells; however this unique 407 
observation has not been verified yet in other studies and awaits replication. 408 
 409 
3.4. Buccal cells and Amyloid 410 
Aβ is the main component of senile plaques appearing in the brains of AD and is generated 411 
by the processing of its precursor AβPP. Since AβPP is ubiquitously expressed, it may be 412 
involved in stimulation and proliferation of keratinocytes where they are mostly expressed 413 
in the basal layer [146]. It is feasible that differences of AβPP expression in the BM could 414 
therefore also reveal information regarding the regeneration potential of the BM in AD. The 415 
expression of AβPP was shown to be present in the buccal pouch of hamsters and AβPP is 416 
believed to promote the development of oral carcinogenesis [147]. The biopsy of oral tissues 417 
for instance has been advocated as an alternate method of detecting amyloid deposition in 418 
amyloidosis [148] confirming that amyloid can accumulate to detectable levels in peripheral 419 
tissue such as the liver in systemic amyloidosis [149]. AβPP has previously been investigated 420 
in young adult Wistar rats and localized by immunohistochemistry in several peripheral 421 
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tissues, i.e. liver, kidney, spleen, pancreas, salivary gland, testis and ovary [150]. Since AβPP 422 
is a protein ubiquitously expressed in humans, it is likely that Aβ protein which is processed 423 
from AβPP and its’ variants (e.g. monomers, dimers, oligomers, etc…) may be a plausible 424 
target to be investigated in the BM of AD patients [151]. It is plausible that a genetic or 425 
acquired predisposition for amyloidogenic processing of AβPP could be evident not only in 426 
the brain but also in epithelial tissues. 427 
 428 
3.5. Buccal cells and DNA damage 429 
Genomic DNA damage has been shown to be associated with AD as discussed earlier [152]. 430 
Genomic instability has been reported to increase with age and therefore the capacity for 431 
DNA damage repair may also be altered [24-26]. In buccal cells a buccal micronucleus 432 
cytome assay was developed by Thomas et al. to score DNA damage, cell death and 433 
regenerative potential [120,153]. A Down’s syndrome cohort was used as a model for 434 
premature ageing and presented a significantly elevated level of MN compared with both 435 
the older and younger control groups (p<0.0001) [154]. The same buccal micronucleus 436 
cytome scoring assay was performed on an Alzheimer’s cohort and showed a slightly 437 
elevated MN score in the AD group when compared to age-matched controls, but this 438 
difference did not reach statistical significance [120]. Genomic changes such as aneuploidy 439 
of both chromosomes 17 and 21, containing respectively the genes coding for Tau and AβPP 440 
[155,156], has also been investigated in buccal cells. Aneuploidy levels of chromosomes 17 441 
and 21 were shown to increase in buccal cells in AD and Down’s syndrome compared to 442 
their respective controls [157]. Additionally, DNA double strand breaks have been detected 443 
in human buccal cells using an immunofluorescent antibody against γH2AX [158], therefore 444 
confirming that MN and γH2AX are two important DNA damage biomarkers that can be 445 
detected and may be altered in buccal cells from patients with AD. Oxidative stress has also 446 
been studied in leukocytes and exfoliated BM using HPLC after DNA isolation [106] and 447 
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because the association between accumulated oxidative DNA damage and ageing is well 448 
documented, it is possible that the BM may show changes in 8-OHdG levels from AD buccal 449 
samples; however this has yet to be tested. 450 
 451 
3.6. Buccal cells and cytological parameters 452 
In a recent study from our group, an automated buccal cell assay was developed using laser 453 
scanning cytometry (LSC) to measure buccal cell neutral lipid, nuclear DNA content and 454 
nuclear shape from clinically diagnosed AD, MCI patients and age- and gender-matched 455 
controls [109]. Findings showed significantly lower levels of neutral lipids in MCI and a 456 
significant increase in DNA content in both MCI and AD compared to controls. The ploidy 457 
distribution of nuclei was also investigated in this study and showed that the increase in 458 
DNA content observed in MCI and AD cases were due to a significant decrease in the 459 
proportion of 2N nuclei with a concomitant increase in the proportion of >2N nuclei. 460 
Additionally, the LSC automated buccal cell assay developed by our group allowed collection 461 
of “circularity” measurements providing information on the shape of buccal cell nuclei. It 462 
was found that nuclei had a significantly more irregular shape in MCI and AD when 463 
compared to controls [109]. These results suggest that the changes in DNA content are due 464 
to hyperdiploid nuclei accumulating with the disease state. ROC curves were also used in this 465 
study for each of the parameters analysed and their combination, generating AUC varying 466 
from 0.763 to 0.837 [109]. It would therefore be of interest to combine this automated assay 467 
with detection of other potential specific protein markers, which may increase the likelihood 468 
of better predictive markers for AD. 469 
 470 
3.7. Buccal cells and telomere length 471 
Absolute telomere length has been investigated in buccal cells of confirmed AD cases and 472 
healthy age- and gender-matched controls. A significantly shorter telomere length was 473 
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observed in buccal cells of the AD group compared to controls (p=0.01). Additionally, in the 474 
same individuals, there was a significant decrease in telomere length in white blood cells 475 
(p<0.0001) [19]. However there was no correlation between buccal cell and lymphocyte 476 
telomere length. This may be partly due to the differences in turnover rates of cell division in 477 
buccal cells compared with lymphocytes. Although the evidence is minimal to-date, buccal 478 
cells and lymphocytes appear to exhibit a reduction in telomere length in AD and therefore, 479 
suggest that other peripheral tissues inducing BM may also be used to assess reductions in 480 
telomere length in AD. 481 
 482 
4. Future perspectives 483 
As populations throughout the world continue to age, the prevalence of AD is expected to 484 
increase dramatically. By 2050 nearly one million new AD cases per year has been estimated, 485 
with this increasing prevalence becoming a global concern threatening to impact heavily on 486 
both social and economic levels [10,159-161]. Therefore biomarkers for an early diagnostic 487 
of the disease would tremendously benefit the community as treatment strategies would 488 
likely to be more effective in preserving brain function if administered early in the disease 489 
process prior to the development of symptoms. Evidence that pathologic changes of AD are 490 
reflected in peripheral tissues such as fibroblasts, olfactory epithelium, whole blood, 491 
platelets, white blood cells and plasma indicates that AD is a systemic disorder and that 492 
these tissues should be considered as a useful source for  potential biomarkers (see Table 1). 493 
However, investigating a minimally invasive tissue such as the BM as a source of biomarkers 494 
with high specificity and sensitivity for AD is yet to be achieved. The BM is an easily 495 
accessible non neuronal tissue, which offers a simple, painless and non-expensive sampling 496 
procedure. Previous findings suggest that the regenerative potential of the buccal mucosa 497 
varies and cytological changes occur within buccal cells following the appearance of AD. 498 
However there is still little known in this area regarding buccal cell differentiation and 499 
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proliferation status. Only a few studies have investigated changes in the oral mucosa in AD 500 
investigating cytological parameters, cell type composition, qualification of Tau, MN, DNA 501 
content, lipids, telomere length as well as chromosome 17 and 21 aneuploidy (see Table 1) 502 
confirming that the BM is a potential tissue for AD diagnostic biomarkers. Therefore, further 503 
research must be undertaken in order to obtain a better understanding of the biology of 504 
buccal cells, to replicate such studies and investigate other potential markers of AD that 505 
might include lipid content, APOE gene expression, AβPP, Aβ, γH2AX, 8-OHdG as well as 506 
others. Longitudinal studies could then be undertaken to capture the variation in biomarkers 507 
with the progression of the disease and the associated cognitive decline. This review 508 
summarizes some of the knowledge gaps in buccal cells as a peripheral tissue for AD 509 
diagnostics. If combined with results from other peripheral tissues, new biomarker sets 510 
could emerge that may identify individuals who are at increased risk or are at an early stage 511 
of AD with much higher certainty. Therefore, investigations involving minimally invasive non-512 
neural tissue for sampling biomarkers cellular origin of MCI/AD risk need to be further 513 
investigated. 514 
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Table 1: Summary of AD biomarkers altered in peripheral tissues. 1133 
 1134 
Peripheral tissue 
investigated  
Parameters measured and outcome Reference(s) 
Fibroblast 
3-fold ↑ MN frequency [32] 
2-fold ↑ Trisomy 21 levels [35] 
1.3-fold ↑ Immunostaining of amyloid pep[des (Aβ40, 
Aβ42)  
[37] 1.3-fold ↓ β-Secretase 1 
6-fold ↑ Rate of cholesterol esterifica[on a^er 48 h  
56% ↑ pool of neutral lipids 
Altered pattern of spreading in culture 
[38] 
70% ↓ Free calcium content 
197% ↑ Bound calcium content [39] 
Whole blood 
TOMM40 alleles ↑ disease risk by 2 [46] 
10% ↓ Red blood cell folate [47] 
AD signature of 12 mi-RNAs identified, compared with 
controls (95% specificity / 91.5% sensitivity) 
[48] 
White blood cell 31% ↓ Telomere length [19] 
Lymphocyte 
↑ Neutral lipid accumulation [75] 
2-fold ↑ Total Tau [52] 
↑ MN frequency in chromosomes 13 and 21 [22,65,66] 
1.15-fold ↓ Telomere length correlated with ↓ 
MMSE scores (r = -0.77) 
[74] 
↑ G1/S checkpoint proteins (Cyclin E, Rb, CDK2 and [83] 
46 
 
E2F-1) 
Leukocyte 
2-fold ↑ Single and double strand breaks combined 
2.6-fold ↑ DNA oxidized pyrimidines  
2-fold ↑ DNA oxidized purines  
 
[57] 
 
Macrophage 19-fold ↑ Chitotriosidase expression level  [55] 
Platelet 
2.1-fold ↓ AβPP Isoforms (130kDa/110kDa) ratio in 
platelet membranes 
[84,85] 
6.5-fold ↓ High kDa/Low kDa forms of Tau ra[o [23] 
Plasma 
↑ Aβ in individuals who further convert to AD [89] 
↑ Aβ42 predicts ↑ AD risk [20] 
↑ Aβ predicts faster cognitive decline [90] 
↑ Insulin growth factor binding protein 2, pancrea[c 
polypeptide, cortisol, vascular cell adhesion molecule, 
superoxide dismutase, interleukin 10 
[43] 
↓ Albumin, Calcium, Zinc (isotope 66), interleukin 17 
4.8-fold ↑ Chitotriosidase level [86] 
3.7-fold ↑ YKL-40 level [88] 
10 lipids panel predicting conversion to MCI or AD 
ROC curve AUC value was 0.96 
[91] 
Nasal cell 
3.7-fold ↑ Abundance ra[ngs for Aβ and 1.8-fold ↑ 
for phosphorylated Tau 
[21] 
1.2-fold ↑ HNE-pyrrole and 1.5-fold ↑ Heme 
oxygenase-1 
[42] 
Buccal cell 
↓ Frequencies of basal, karyorrhectic and condensed 
chromatin cells 
[120] 
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1.24-fold ↓ Nuclei/Cytoplasmic size ra[o in 
intermediate cells [122] 
1.5-fold ↓ Intermediate cell frequency 
↑ MN frequency in Down’s syndrome [121,154] 
1.75-fold ↑ Tau correlated (r = 0.43) with ↑ Tau in 
CSF 
[103] 
1.2-fold ↑ Aneuploidy levels of chromosome 17 
[157] 
1.5-fold ↑ Aneuploidy levels of chromosome 21 
2-fold ↓ Telomere length [19] 
1.7 fold ↑ and 1.5 fold ↑ DNA content in MCI and AD, 
respectively 
1.5 fold ↓ Neutral lipid content in MCI 
1.7 fold ↓ and 1.5 fold ↓ 2N nuclei popula[on in MCI 
and AD, respectively 
↑ irregular nuclear shape 
[109] 
 1135 
 1136 
Abbreviations: Aβ, Amyloid-β; AD, Alzheimer’s disease; AβPP, Amyloid-β protein precursor; 1137 
CSF, Cerebrospinal fluid; mi-RNAs, microRNAs; MMSE, Mini-mental state examination; MN, 1138 
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Figure legends 1198 
 1199 
Figure 1: Diagrammatic representation of a cross section of normal buccal mucosa.  1200 
The schematic is illustrative of a healthy individual’s buccal mucosa, highlighting the 1201 
different cell layers and possible spatial relationships of the various cell types present. 1202 
 1203 
Figure 2: Changes in the buccal cytome are associated with AD.  1204 
The frequency (%) of different buccal cell types scored for AD (n=31) and their age- and 1205 
gender-matched controls (n=31); for (A) condensed chromatin cells, (B) basal cells and (C) 1206 
karyorrhectic cells. Representative images of the buccal cell nuclei (which are one of the 1207 
parameters used to define the buccal cytome in addition to the cytoplasm area and staining 1208 
intensity) are shown as insets within each graph. Abbreviations: AD, Alzheimer’s disease; 1209 
Data are Mean +/- SD. ****p<0.0001. Adapted from Thomas et al. 2007 [120]. 1210 
 1211 
Figure 3: Immunocytochemistry techniques showed a difference in expression of 1212 
Cytokeratin 5 and 13 within buccal cells.  1213 
(A) Schematic showing the differential expression of cytokeratins within the buccal cell 1214 
layers. (B) Cytokeratin 5 and 13 were detected using an immunocytochemistry dual-staining 1215 
technique, cells expressing cytokeratin 13 were detected with a secondary antibody 488 1216 
Alexa Fluor (Green) and cells expressing cytokeratin 5 were detected with a secondary 1217 
antibody 647 Alexa Fluor (Red). (C) Using Laser Scanning Cytometry different populations of 1218 
cells were scored depending on the type of cytokeratin expressed. (D) From the scattergram 1219 
in (C), the percentage of buccal cell types based on cytokeratin 5/13 expression is shown. 1220 
